The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects "SPIRE-1"

Terminated

Phase 3 Results N/A

References

Related Links

Sources for Trial Information